J Menopausal Med.  2017 Aug;23(2):79-84. 10.6118/jmm.2017.23.2.79.

Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy

Affiliations
  • 1Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea. leejrmd@snu.ac.kr
  • 2Department of Obstetrics and Gynecology, Kyung Hee University Hospital at Gangdong, Seoul, Korea.
  • 3Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.
  • 4Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea.

Abstract

Ospemifene"”a third-generation selective estrogen receptor modulator approved by the Food and Drug Administration in 2013"”is an oral medication for the treatment of dyspareunia. In postmenopausal women with vulvovaginal atrophy, ospemifene significantly improves the structure and pH levels of the vagina, reducing dyspareunia. It is available as a 60-mg tablet; hence, women who may have had prior difficulty with vaginal administration or on-demand use of nonprescription lubricants and moisturizers would likely prefer this form of treatment. Preclinical studies demonstrated that ospemifene has an estrogen agonist action on the bone, reducing the cell proliferation of ductal carcinoma in an in situ model. Studies evaluating the safety of treatment for up to 52 weeks have shown that ospemifene is a safe medication with minimal impact on the endometrium. Further studies with larger number of subjects are necessary to better conclude its effects and long-term safety.

Keyword

Atrophy; Dyspareunia; Menopause; Tamoxifen; Vulva

MeSH Terms

Administration, Intravaginal
Atrophy*
Carcinoma, Ductal
Cell Proliferation
Dyspareunia
Endometrium
Estrogens
Female
Humans
Hydrogen-Ion Concentration
Lubricants
Menopause
Selective Estrogen Receptor Modulators
Tamoxifen
United States Food and Drug Administration
Vagina
Vulva
Estrogens
Lubricants
Selective Estrogen Receptor Modulators
Tamoxifen

Figure

  • Fig. 1 Chemical structures of ospemifene, tamoxifen, and toremifene.


Cited by  1 articles

Therapeutic Approaches to Atrophic Vaginitis in Postmenopausal Women: A Systematic Review with a Network Meta-analysis of Randomized Controlled Trials
Arum Lee, Tae Hee Kim, Hae Hyeog Lee, Yeon Suk Kim, Temuulee Enkhbold, Bora Lee, Yoo Jin Park, Kisung Song
J Menopausal Med. 2018;24(1):1-10.    doi: 10.6118/jmm.2018.24.1.1.


Reference

1. Calleja-Agius J, Brincat MP. Urogenital atrophy. Climacteric. 2009; 12:279–285.
2. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause. 2008; 15:661–666.
3. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009; 6:2133–2142.
4. Kim SH, Park ES, Kim TH. Rejuvenation using platelet-rich plasma and lipofilling for vaginal atrophy and lichen sclerosus. J Menopausal Med. 2017; 23:63–68.
5. Burich R, DeGregorio M. Current treatment options for vulvovaginal atrophy. Expert Rev Obstet Gynecol. 2011; 6:141–151.
6. Park HM, Kang BM, Kim JG, Yoon BK, Lee BI, Cho SH, et al. The effect of black cohosh with St. John's wort (Feramin-Q(R)) on climacteric symptoms: multicenter randomized double-blind placebo-controlled trial. Korean J Obstet Gynecol. 2005; 48:2403–2413.
7. Hong SN, Kim JH, Kim HY, Kim A. Effect of black cohosh on genital atrophy and its adverse effect in postmenopausal women. J Korean Soc Menopause. 2012; 18:106–112.
8. Kim M, Choi H. Changes in atrophic symptoms, the vaginal maturation index, and vaginal pH in postmenopausal women treated with vaginal estrogen tablets. J Korean Soc Menopause. 2010; 16:162–169.
9. Davies GC, Huster WJ, Lu Y, Plouffe L Jr, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol. 1999; 93:558–565.
10. Gennari L, Merlotti D, Valleggi F, Nuti R. Ospemifene use in postmenopausal women. Expert Opin Investig Drugs. 2009; 18:839–849.
11. Qu Q, Zheng H, Dahllund J, Laine A, Cockcroft N, Peng Z, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology. 2000; 141:809–820.
12. Goldstein SR, Bachmann GA, Koninckx PR, Lin VH, Portman DJ, Ylikorkala O. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric. 2014; 17:173–182.
13. Koskimies P, Turunen J, Lammintausta R, Scheinin M. Single-dose and steady-state pharmacokinetics of ospemifene, a selective estrogen receptor modulator, in postmenopausal women. Int J Clin Pharmacol Ther. 2013; 51:861–867.
14. Unkila M, Kari S, Yatkin E, Lammintausta R. Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause. J Steroid Biochem Mol Biol. 2013; 138:107–115.
15. Kangas L, Unkila M. Tissue selectivity of ospemifene: pharmacologic profile and clinical implications. Steroids. 2013; 78:1273–1280.
16. Hellmann-Blumberg U, Taras TL, Wurz GT, DeGregorio MW. Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene. Breast Cancer Res Treat. 2000; 60:63–70.
17. Burich RA, Mehta NR, Wurz GT, McCall JL, Greenberg BE, Bell KE, et al. Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model. Menopause. 2012; 19:96–103.
18. Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol. 2001; 77:271–279.
19. Wurz GT, Read KC, Marchisano-Karpman C, Gregg JP, Beckett LA, Yu Q, et al. Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice. J Steroid Biochem Mol Biol. 2005; 97:230–240.
20. Wurz GT, Hellmann-Blumberg U, DeGregorio MW. Pharmacologic effects of ospemifene in rhesus macaques: a pilot study. Basic Clin Pharmacol Toxicol. 2008; 102:552–558.
21. Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010; 17:480–486.
22. Simon JA, Lin VH, Radovich C, Bachmann GA. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2013; 20:418–427.
23. Simon J, Portman D, Mabey RG Jr. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women. Maturitas. 2014; 77:274–281.
24. Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013; 20:623–630.
25. Cui Y, Zong H, Yan H, Li N, Zhang Y. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med. 2014; 11:487–497.
26. McCall JL, DeGregorio MW. Pharmacologic evaluation of ospemifene. Expert Opin Drug Metab Toxicol. 2010; 6:773–779.
27. Portman D, Palacios S, Nappi RE, Mueck AO. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas. 2014; 78:91–98.
28. Nappi RE, Panay N, Bruyniks N, Castelo-Branco C, De Villiers TJ, Simon JA. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric. 2015; 18:233–240.
29. Qu Q, Härkönen PL, Väänänen HK. Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J Cell Biochem. 1999; 73:500–507.
30. Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015; 100:3975–4011.
31. Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause. 2003; 10:433–439.
32. Komi J, Lankinen KS, Härkönen P, DeGregorio MW, Voipio S, Kivinen S, et al. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause. 2005; 12:202–209.
33. Ylikorkala O, Cacciatore B, Halonen K, Lassila R, Lammintausta R, Rutanen EM, et al. Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women. Menopause. 2003; 10:440–447.
34. Archer DF, Altomare C, Jiang W, Cort S. Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data. Menopause. 2017; DOI: 10.1097/gme.0000000000000900.
35. Shionogi Inc. Osphena®: prescribing package insert. Florham Park, NJ: Shionogi Inc;2015.
36. Lehtinen T, Tolonen A, Turpeinen M, Uusitalo J, Vuorinen J, Lammintausta R, et al. Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene. Biopharm Drug Dispos. 2013; 34:387–395.
Full Text Links
  • JMM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr